Zegalogue
Authorised
This medicine is authorised for use in the European Union
dasiglucagon
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Zegalogue is used for treating severe hypoglycaemia (low blood glucose levels) in adults and children from 6 years of age who have diabetes mellitus.
Hypoglycaemia can occur when diabetes medicines cause glucose levels to fall too low. In severe cases, patients can faint or become unconscious, and they must be treated urgently to raise their glucose levels.
Zegalogue contains the active substance dasiglucagon.
Zegalogue is given by injection under the skin in the lower abdomen, buttocks, thigh or outer upper arm as soon as signs of severe hypoglycaemia are recognised. If there is no response, an additional dose from another device may be given after 15 minutes.
Patients and their caregivers should receive information about the signs and symptoms of severe hypoglycaemia. As severe hypoglycaemia requires the help of others, the patient should be instructed to inform those around them about Zegalogue and how to use it.
The medicine can only be obtained with a prescription. For more information about using Zegalogue, see the package leaflet or contact your doctor or pharmacist.
The active substance in Zegalogue works in a similar way to a natural hormone in the body called glucagon. In patients with low levels of blood glucose, the medicine causes the liver to release stored glucose into the bloodstream, thereby reducing symptoms of hypoglycaemia.
Three main studies showed that Zegalogue was effective at restoring blood glucose levels in patients with type 1 diabetes whose blood glucose levels were very low after insulin treatment.
In the first study in 168 adults, patients who had Zegalogue recovered in 10 minutes while those given placebo recovered in 40 minutes. There were similar results in a second study in 44 adults where patients who had Zegalogue recovered in 10 minutes while those who had placebo recovered after 35 minutes.
The third study involved 41 children from 6 years of age. In this study, patients who had Zegalogue also recovered in 10 minutes, while those on placebo recovered after 30 minutes.
For the full list of side effects and restrictions with Zegalogue, see the package leaflet.
The most common side effects with Zegalogue (which may affect more than 1 in 10 people) include nausea (feeling sick) and vomiting. Another common side effect which may affect up to 1 in 10 people is headache.
Zegalogue must not be used in patients with phaeocromocytoma (a tumour in the adrenal glands).
The main studies showed that Zegalogue was effective at restoring blood glucose levels in people with hypoglycaemia caused by insulin treatment. The side effects are considered acceptable. The European Medicines Agency therefore decided that Zegalogue ’s benefits are greater than its risks and that it can be authorised for use in the EU.
The company that markets Zegalogue will provide healthcare professionals, patients and caregivers with educational materials, a leaflet and an instructional video, on how to use the medicine.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zegalogue have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Zegalogue are continuously monitored. Suspected side effects reported with Zegalogue are carefully evaluated and any necessary action taken to protect patients.
Zegalogue received a marketing authorisation valid throughout the EU on 24 July 2024.
Product information
Latest procedure affecting product information:
VR/0000263475
22/04/2025
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Zegalogue
- Active substance
- dasiglucagon hydrochloride
- International non-proprietary name (INN) or common name
- dasiglucagon
- Therapeutic area (MeSH)
- Diabetes Mellitus
- Anatomical therapeutic chemical (ATC) code
- H04AA02
Pharmacotherapeutic group
Pancreatic hormonesTherapeutic indication
Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
News on Zegalogue
This page was last updated on